Agile Therapeutics, Inc. (AGRX)
Aug 26, 2024 - AGRX was delisted (reason: acquired by Insud Pharma)
1.510
0.00 (0.00%)
Inactive · Last trade price on Aug 26, 2024
Agile Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 | Dec '19 Dec 31, 2019 | Sep '19 Sep 30, 2019 |
| 21.57 | 21.5 | 19.59 | 19.98 | 16.31 | 12.94 | 10.88 | 8.4 | 6.69 | 5.75 | 4.1 | 3.34 | 2.05 | 0.87 | 0.75 | - | - | - | - | - | |
Revenue Growth (YoY) | 32.22% | 66.17% | 80.02% | 137.74% | 143.95% | 125.13% | 165.40% | 151.86% | 226.20% | 564.28% | 447.53% | - | - | - | - | - | - | - | - | - |
Cost of Revenue | 7.84 | 8.66 | 8.98 | 8.44 | 7.39 | 7.31 | 6.84 | 10.88 | 12.17 | 11.08 | 10.72 | 5.3 | 2.59 | 1.44 | 0.28 | - | - | - | - | - |
Gross Profit | 13.73 | 12.84 | 10.62 | 11.54 | 8.93 | 5.62 | 4.05 | -2.48 | -5.48 | -5.34 | -6.62 | -1.96 | -0.54 | -0.58 | 0.47 | - | - | - | - | - |
Selling, General & Admin | 25.49 | 26.82 | 28.27 | 31.72 | 32.62 | 35.43 | 42.23 | 49.85 | 54.24 | 59.64 | 58.14 | 55.85 | 54.08 | 44.62 | 36.02 | 25.09 | 16.24 | 11.63 | 9 | 7.3 |
Research & Development | 1.79 | 1.96 | 2.23 | 2.52 | 2.61 | 2.76 | 3.25 | 4.58 | 5.38 | 5.38 | 6.25 | 7.58 | 9.65 | 12.46 | 13.5 | 13.33 | 12.02 | 10.14 | 9.86 | 8.88 |
Operating Expenses | 27.28 | 28.77 | 30.5 | 34.25 | 35.22 | 38.19 | 45.48 | 54.43 | 59.62 | 65.02 | 64.39 | 63.43 | 63.73 | 57.08 | 49.52 | 38.42 | 28.26 | 21.77 | 18.86 | 16.18 |
Operating Income | -13.56 | -15.93 | -19.88 | -22.71 | -26.3 | -32.57 | -41.43 | -56.91 | -65.1 | -70.36 | -71.01 | -65.39 | -64.27 | -57.66 | -49.05 | -38.42 | -28.26 | -21.77 | -18.86 | -16.18 |
Interest Expense | -0.83 | -1.2 | -1.42 | -1.55 | -2.21 | -2.66 | -3.13 | -3.7 | -3.69 | -3.86 | -3.91 | -3.82 | -3.72 | -3.63 | -3.11 | -2.21 | -1.3 | -0.4 | - | -0.16 |
Interest & Investment Income | 0.08 | 0.07 | 0.08 | 0.09 | 0.13 | 0.11 | 0.08 | 0.05 | 0.01 | 0.01 | 0.03 | 0.05 | 0.09 | 0.19 | 0.31 | 0.37 | 0.4 | 0.35 | 0.25 | 0.25 |
Other Non Operating Income (Expenses) | -1.55 | 9.28 | 6.76 | 10.24 | 20.45 | 25.82 | 25.52 | 26 | 12.26 | 5.21 | 3.83 | - | - | - | - | - | - | - | - | - |
EBT Excluding Unusual Items | -15.86 | -7.79 | -14.47 | -13.93 | -7.93 | -9.3 | -18.97 | -34.56 | -56.53 | -69 | -71.07 | -69.16 | -67.91 | -61.1 | -51.85 | -40.25 | -29.16 | -21.82 | -18.61 | -16.09 |
Merger & Restructuring Charges | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.3 |
Gain (Loss) on Sale of Assets | - | - | - | - | -11.12 | -11.12 | -11.12 | -11.12 | - | - | - | - | - | - | - | - | - | - | - | - |
Pretax Income | -15.86 | -7.79 | -14.47 | -13.93 | -19.06 | -20.42 | -30.09 | -45.69 | -56.53 | -69 | -71.07 | -69.16 | -67.91 | -61.1 | -51.85 | -40.25 | -29.16 | -21.82 | -18.61 | -16.4 |
Income Tax Expense | - | - | - | - | - | - | -4.68 | -4.68 | -4.68 | -4.68 | - | - | - | - | - | - | - | - | - | - |
Net Income | -15.86 | -7.79 | -14.47 | -13.93 | -19.06 | -20.42 | -25.41 | -41.01 | -51.86 | -64.32 | -71.07 | -69.16 | -67.91 | -61.1 | -51.85 | -40.25 | -29.16 | -21.82 | -18.61 | -16.4 |
Net Income to Common | -15.86 | -7.79 | -14.47 | -13.93 | -19.06 | -20.42 | -25.41 | -41.01 | -51.86 | -64.32 | -71.07 | -69.16 | -67.91 | -61.1 | -51.85 | -40.25 | -29.16 | -21.82 | -18.61 | -16.4 |
Net Income Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 4 | 3 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shares Change (YoY) | 308.85% | 378.81% | 398.99% | 576.06% | 1548.13% | 1112.69% | 790.51% | 436.32% | 47.30% | 21.61% | 14.63% | 13.85% | 25.21% | 47.51% | 71.31% | 85.60% | 87.14% | 68.92% | 44.05% | 23.45% |
EPS (Basic) | -3.64 | -2.52 | -6.71 | -8.59 | -17.88 | -31.67 | -58.79 | -171.06 | -801.95 | -1210.03 | -1464.21 | -1547.07 | -1546.94 | -1397.68 | -1224.62 | -1025.19 | -831.77 | -736.32 | -752.79 | -774.96 |
EPS (Diluted) | -3.64 | -2.52 | -6.71 | -8.65 | -17.88 | -31.67 | -58.79 | -171.06 | -801.95 | -1210.03 | -1464.21 | -1547.07 | -1546.94 | -1397.68 | -1224.62 | -1027.89 | -831.77 | -736.32 | -752.79 | -774.96 |
EPS Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Additional Metrics
Fiscal Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 | Q1 2020 | Q4 2019 | Q3 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Mar '24 Mar 31, 2024 | Dec '23 Dec 31, 2023 | Sep '23 Sep 30, 2023 | Jun '23 Jun 30, 2023 | Mar '23 Mar 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Jun '22 Jun 30, 2022 | Mar '22 Mar 31, 2022 | Dec '21 Dec 31, 2021 | Sep '21 Sep 30, 2021 | Jun '21 Jun 30, 2021 | Mar '21 Mar 31, 2021 | Dec '20 Dec 31, 2020 | Sep '20 Sep 30, 2020 | Jun '20 Jun 30, 2020 | Mar '20 Mar 31, 2020 | Dec '19 Dec 31, 2019 | Sep '19 Sep 30, 2019 |
Free Cash Flow | -1.71 | -10.46 | -9.58 | -11.31 | -28.38 | -22.8 | -36.08 | -51.19 | -53.14 | -65.61 | -65.47 | -66.2 | -62.95 | -54.36 | -47.66 | -33.6 | -23.32 | -18.87 | -15.79 | -15.59 |
Free Cash Flow Per Share | -0.39 | -3.39 | -4.44 | -6.98 | -26.63 | -35.36 | -83.48 | -213.53 | -821.76 | -1234.20 | -1348.92 | -1480.85 | -1433.88 | -1243.42 | -1125.69 | -855.80 | -665.12 | -636.90 | -638.74 | -736.67 |
Gross Margin | 63.63% | 59.74% | 54.18% | 57.75% | 54.71% | 43.48% | 37.19% | -29.54% | -81.99% | -92.90% | -161.35% | -58.84% | -26.24% | -66.82% | 62.35% | - | - | - | - | - |
Operating Margin | -62.85% | -74.12% | -101.49% | -113.69% | -161.20% | -251.77% | -380.69% | -677.39% | -973.58% | -1224.43% | -1731.41% | -1960.07% | -3135.12% | -6665.66% | -6549.13% | - | - | - | - | - |
Profit Margin | -73.52% | -36.24% | -73.83% | -69.72% | -116.81% | -157.83% | -233.48% | -488.11% | -775.46% | -1119.46% | -1732.92% | -2073.05% | -3312.63% | -7063.35% | -6922.96% | - | - | - | - | - |
Free Cash Flow Margin | -7.91% | -48.65% | -48.88% | -56.61% | -173.95% | -176.24% | -331.50% | -609.31% | -794.62% | -1141.82% | -1596.46% | -1984.32% | -3070.54% | -6283.82% | -6363.68% | - | - | - | - | - |
EBITDA | -13.15 | -15.54 | -19.5 | -22.33 | -25.76 | -31.53 | -39.9 | -54.9 | -62.8 | -68.09 | -68.78 | -63.61 | -62.99 | -56.88 | -48.78 | -38.23 | -28.09 | -21.6 | -18.7 | -16.05 |
EBITDA Margin | -60.99% | -72.28% | -99.52% | -111.80% | -157.88% | -243.74% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
D&A For EBITDA | 0.4 | 0.4 | 0.39 | 0.38 | 0.54 | 1.04 | 1.53 | 2.02 | 2.31 | 2.27 | 2.22 | 1.78 | 1.28 | 0.78 | 0.28 | 0.19 | 0.17 | 0.16 | 0.16 | 0.13 |
EBIT | -13.56 | -15.93 | -19.88 | -22.71 | -26.3 | -32.57 | -41.43 | -56.91 | -65.1 | -70.36 | -71.01 | -65.39 | -64.27 | -57.66 | -49.05 | -38.42 | -28.26 | -21.77 | -18.86 | -16.18 |
EBIT Margin | -62.85% | -74.12% | -101.49% | -113.69% | -161.20% | -251.77% | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Advertising Expenses | - | - | - | - | - | - | 8.2 | - | - | - | 13.8 | - | - | - | 5.5 | - | - | - | - | - |